New 'Living Drug' trial targets tough blood cancers

This early-stage study is testing the safety and initial effectiveness of a new type of CAR-T cell therapy called BAFFR CAR-T in adults with B-cell leukemia or lymphoma that has come back or not responded to standard treatments. Doctors will give the therapy to a small group of patients and carefully monitor for side effects and signs that the treatment is working against the cancer. The main goal is to find a safe dose and see if this approach shows promise for controlling these difficult cancers.